DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9.220,715 B2 Demopulos Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9.220,715 B2 Demopulos Et Al US009220715B2 (12) United States Patent (10) Patent No.: US 9.220,715 B2 Demopulos et al. (45) Date of Patent: *Dec. 29, 2015 (54) TREATMENT OF ADDICTION AND A613 L/454 (2006.01) IMPULSE-CONTROL DISORDERS USING A613 L/485 (2006.01) PDE7 INHIBITORS (Continued) (71) Applicant: Omeros Corporation, Seattle, WA (US) (52) U.S. Cl. CPC ........... A6 IK3I/5513 (2013.01); A61 K3I/I35 (72) Inventors: Gregory A. Demopulos, Mercer Island, (2013.01); A61 K3I/I37 (2013.01); A61 K WA (US); George A. Gaitanaris, 31/197 (2013.01); A6IK3I/337 (2013.01); Seattle, WA (US); Roberto A61K 31/35 (2013.01); A61 K3I/357 Ciccocioppo, Camerino (IT) (2013.01); A61 K3I/381 (2013.01); A61 K 3 1/385 (2013.01); A61 K31/4015 (2013.01): (73) Assignee: Omeros Corporation, Seattle, WA (US) A61K 31/4025 (2013.01); A61 K31/4162 (*) Notice: Subject to any disclaimer, the term of this (2013.01); A61 K3I/4178 (2013.01); A61 K patent is extended or adjusted under 35 31/433 (2013.01); A61K 31/435 (2013.01); U.S.C. 154(b) by 0 days. A6 IK3I/44 (2013.01); A61 K3I/4439 (2013.01); A61 K3I/454 (2013.01); A61 K This patent is Subject to a terminal dis- 3 1/46 (2013.01); A61K3I/485 (2013.01); claimer. A6 IK3I/496 (2013.01); A61 K3I/4985 (2013.01); A61 K3I/505 (2013.01); A61 K (21) Appl. No.: 13/835,607 31/517 (2013.01); A6IK3I/519 (2013.01); (22) Filed: Mar 15, 2013 A61 K3I/527 (2013.01); A61K3I/53 (2013.01); A61 K3I/5377 (2013.01); A61 K (65) Prior Publication Data 3 I/55 (2013.01); A61K 45/06 (2013.01) US 2013/02675O2A1 Oct. 10, 2013 ( 58) Field of Classification Search Cl. TU, CPC ........... A61K31/5513; A61K 31/5377; A61 K 3 1/53: A61K 31/4985; A61K 31/496; A61 K Related U.S. Application Data 31/519; A61 K31/527; A61 K31/46; A61 K 31/435; A61 K31/4439; A61K 31/433; (63) Continuation-in-part of application No. 13/290,868, A61K 31/41.78: A61K 31/4162: A61 K filed on Nov. 7, 2011. 31/4025; A61K 31/35; A61K 45/06 (60) Provisional application No. 61/643,611, filed on May See application file for complete search history. 7, 2012, provisional application No. 61/482,994, filed on May 5, 2011, provisional application No. (56) References Cited 61/411,437, filed on Nov. 8, 2010, provisional U.S. PATENT DOCUMENTS application No. 61/411,431, filed on Nov. 8, 2010. 5,610,288 A 3, 1997 Rubenstein (51) Int. Cl. 5,718,709 A 2f1998 Considine et al. A 6LX3/553 (2006.01) (Continued) A 6LX3/5377 (2006.01) A6 IK3I/53 (2006.01) FOREIGN PATENT DOCUMENTS A6 IK3I/4985 (2006.01) A6 IK3I/496 (2006.01) BR O607402-2 A2 9, 2009 A 6LX3/59 (2006.01) DE 199 SO 647 A1 10, 1999 A 6LX3/527 (2006.01) (Continued) A6 IK3 L/46 (2006.01) A6 IK3I/435 (2006.01) OTHER PUBLICATIONS A6 IK3I/4439 (2006.01) Siuciak, J., et al., “Inhibition of the Striatum-Enriched A6 IK3I/433 (2006.01) Phosphodiesterase PDE10A: A Novel Approach to the Treatment of A6 IK3I/478 (2006.01) Psychosis.” Neuropharmacology 51:386-396 (2006). A6 IK3I/4I62 (2006.01) (Continued) A6 IK3I/4025 (2006.01) A6 IK3I/35 (2006.01) A6 IK 45/06 (2006.01) Primary Examiner — Renee Claytor A6 IK3I/35 (2006.01) (74) Attorney, Agent, or Firm — Marcia S. Kelbon A6 IK3I/37 (2006.01) A 6LX3/97 (2006.01) (57) ABSTRACT A6 IK3I/337 (2006.01) This disclosure is directed to treatment of addictions and A 6LX3L/357 (2006.01) primary impulse-control disorders using phosphodiesterase 7 A6 IK3I/38 (2006.01) (PDE7) inhibitors, alone or in combination with other thera A6 IK3I/385 (2006.01) peutic agents. A6 IK3I/405 (2006.01) A6 IK3I/44 (2006.01) 34 Claims, 47 Drawing Sheets US 9.220,715 B2 Page 2 (51) Int. Cl. EP 1348 701 A1 3f2002 A 6LX3L/505 (2006.01) E. 13. A 3.583 A 6LX3/57 (2006.01) EP 1775 298 A1 7/2005 A6 IK3I/55 (2006.01) ES 2308916 12/1987 RU 2351 371 4/2009 (56) References Cited WO WO 94.21244 9, 1994 WO WO 88,04399 6, 1998 U.S. PATENT DOCUMENTS WO WOOOf 682O3 11, 2000 WO WOOOf 68230 11, 2000 5,739,119 A 4, 1998 Galli et al. WO WOO1,29049 A2 4, 2001 5,759,829 A 6, 1998 Shewmaker et al. WO WOO1/32175 A1 5, 2001 5,789,573 A 8, 1998 Baker et al. WO WOO1/32618 A1 5. 2001 5,801,154 A 9, 1998 Baracchini et al. WO WOO1,34601 A2 5, 2001 6,146,876. A 1 1/2000 Robision et al. WO WOO1,364.25 A2 5, 2001 6,531.498 B1 3/2003 Eggenweiler et al. WO WOO1,62904 A1 8/2001 6,613,778 B1 9/2003 Eggenweiler et al. WO WOO 1/74.786 A1 10, 2001 6,617.357 B2 9/2003 Aubart et al. WO WOO1,982.74 A2 12/2001 6,649,592 B1 1 1/2003 Larson WO WOO2,28847 A1 4, 2002 6,737,436 B1 5/2004 Eggenweiler et al. WO WOO2,40449 A1 5. 2002 6,753,340 B2 6/2004 Vergne et al. WO WO O2/4O450 A1 5, 2002 6,818,651 B2 11/2004 Weinbrenner et al. WO WO O2/O74754 A1 9, 2002 6,838,559 B2 1/2005 Vaccaro et al. WO WO O2/O76953 A1 10, 2002 6,849,638 B2 2/2005 Stolle et al. WO WO O2/O85894 A1 10, 2002 6,852,720 B2 2/2005 Vergne et al. WO WO O2/085906 A2 10, 2002 6,884,800 B1 4/2005 Eggenweiler et al. WO WO O2/O87513 A2 11/2002 6,903,109 B2 6/2005 Heintzelman et al. WO WO O2/O87519 A2 11/2002 6,936,609 B2 8/2005 Ergilden et al. WO WO O2/O88079 A2 11/2002 6,958,328 B2 10/2005 Heintzelman et al. WO WO 02/088080 A2 11/2002 7,022,849 B2 4/2006 Pitts et al. WO WO 02/088138 A1 11, 2002 7,087.614 B2 8, 2006 Guo et al. WO WO 02/102313 A2 12/2002 7,122,565 B2 10/2006 Vergne et al. WO WO 02/102314 A2 12/2002 7,214,676 B2 5/2007 Bernardelli et al. WO WO O2/102315 A2 12/2002 7,268,128 B2 9/2007 Inoue et al. WO WO O2/O53975 A1 3f2003 7.491,742 B2 2/2009 Eggenweiler et al. WO WOO3,053975 A1 T 2003 7,498.334 B2 3/2009 Eggenweiler et al. WO WOO3,055882 A1 T 2003 7,579,455 B2 8/2009 Paolo et al. WO WOO3,057149 A2 7, 2003 7932,250 B2 4/2011 Inoue et al. WO WO 03/064389 A1 8, 2003 2002/0156064 A1 10, 2002 Aubart et al. WO WOO3,082.277 A1 10, 2003 2002fO198198 A1 12/2002 Bernardelli et al. WO WOO3,082839 A1 10, 2003 2003/0045557 A1 3/2003 Vergne et al. WO WO 03/088963 A1 10, 2003 2003/0092721 A1 5, 2003 Pitts et al. WO WO 2004/026818 A1 4, 2004 2003/00929.08 A1 5, 2003 Pitts et al. WO WO 2004/044196 A1 5, 2004 2003/010.0571 A1 5/2003 Vaccaro et al. WO WO 2004/065391 A1 8/2004 2003. O104974 A1 6, 2003 Pitts et al. WO WO 2004/111053 A1 12/2004 2003/01 19829 A1 6, 2003 Stolle et al. WO WO 2004/111054 A1 12/2004 2003/01628O2 A1 8/2003 Guo et al. WO WO 2006/004.04.0 A1 1/2006 2003/019 1167 A1 10/2003 Vergne et al. WO WO 2006/092691 A1 9, 2006 2003/0212089 A1 11/2003 Heintzelman et al. WO WO 2006/092692 A1 9, 2006 2004/0044212 A1 3f2004 Weinbrenner et al. WO WO 2007/038551 A2 4, 2007 2004/0082578 A1 4/2004 Heintzelman et al. WO WO 2007/047978 A2 4, 2007 2004/0106631 A1 6/2004 Bernardelli et al. WO WO 2007/063391 6, 2007 2004/O127707 A1 7, 2004 Sterk WO WO 2008, 113881 A1 9, 2008 2004/0249148 Al 12/2004 Ergüden et al. WO WO 2008, 130619 A2 10, 2008 2005/005968.6 A1 3/2005 Eggenweiler et al. WO WO 2008. 142550 A2 11/2008 2005/0148604 A1 7/2005 Inoue et al. WO WO 2009/140309 A2 11/2009 2005/0222138 A1 10, 2005 Ohhata et al. WO WO 2010/027975 A1 3f2010 2006/0116516 A1 6, 2006 Pitts et al. WO WO 2010/030851 A1 3f2010 2006/0128.707 A1 6/2006 Inoue et al. WO WO 2010.109148 A1 9, 2010 2006/O128728 A1 6/2006 Inoue et al. WO WO 2010/116088 A2 10, 2010 2006/0154949 A1 7/2006 Heintzelman et al. 2006/0229306 A1 10, 2006 Terricabras Belart et al. OTHER PUBLICATIONS 2007.0049558 A1 3, 2007 Bernardelli et al. 2007/OO72899 A1 3/2007 Johnson et al. Miro, X., et al., “Differential Distribution of cAMP-Specific 2007/0129388 A1 6, 2007 Rawson et al. Phosphodiesterase 7A mRNA in Rat Brain and Peripheral Organs.” 2007/0208029 A1 9, 2007 Barlow et al. Synapse, 40:201-214 (2001). 3:29:29: A. 2587 S. et al. 1 Reyes-Irrisari, E., et al., “Neuronal Expression of cAMP-Specific 2008/0260643 A1 10, 2008 iA cal Phosphodiesterase 7B mRNA in the Rat Brain.” Neuroscience 2008/0282364 A1 11/2008 Black et al.
Load more

Recommended publications
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • 6-Hydroxydopamine Lesions of The
    The Journal of Neuroscience, May 1994, 14(5): 2531-2544 6-Hydroxydopamine Lesions of the Prefrontal Cortex in Monkeys Enhance Performance on an Analog of the Wisconsin Card Sort Test: Possible Interactions with Subcortical Dopamine A. C. Roberts,’ M. A. De Salvia,” L. S. Wilkinson,’ P. Collins,i J. L. Muir,’ 6. J. Everitt,* and T. W. Robbins’ Departments of ‘Experimental Psychology and ‘Anatomy, University of Cambridge, Cambridge, CB2 3EB, United Kingdom The effects of 6-hydroxydopamine lesions of the prefrontal A disruption of cognitive functions normally associatedwith cortex in monkeys were investigated on two cognitive tests damage to the prefrontal cortex has been reported in a number of prefrontal function, spatial delayed response, and atten- of neurodegenerative disorders including Parkinson’s disease tional set shifting. The latter test provided a componential (PD) (Lees and Smith, 1983; Taylor et al., 1986; Canavan et analysis of the Wisconsin Card Sort Test, a commonly used al., 1989) and progressive supranuclear palsy (PSP) (Albert et clinical test of frontal lobe function in man. Acquisition of a al., 1974; Pillon et al., 1986; Grafman et al., 1990). In the visual compound discrimination requiring a shift of attention absenceof structural pathology within the prefrontal cortex in from one dimension to another (extradimensional shift), for these disorders, such cognitive dysfunctions may be attributed example, shapes to lines, was significantly improved. This to either a disturbance of prefrontal cortical modulation, as a
    [Show full text]
  • Inhibition of Monoamine Oxidase in 5
    Br. J. Pharmac. (1985), 85, 683-690 Inhibition ofmonoamine oxidase in 5- hydroxytryptaminergic neurones by substitutedp- aminophenylalkylamines Anna-Lena Ask, Ingrid Fagervall, L. Florvall, S.B. Ross1 & Susanne Ytterborn Research Laboratories, Astra Likemedel AB, S-151 85 Si3dertilje, Sweden 1 A series ofsubstituted p-aminophenethylamines and some related compounds were examined with regards to the inhibition ofmonoamine oxidase (MAO) in vivo inside and outside 5-hydroxytryptamin- ergic neurones in the rat hypothalamus. This was recorded as the protection against the irreversible inhibition of MAO produced by phenelzine by determining the remaining deaminating activity in the absence and presence ofcitalopram using a low (0.1 yIM) concentration of ['4CJ-5-hydroxytryptamine (5-HT) as substrate. 2 Some ofthe phenethylamines were much more potent inside than outside the 5-hydroxytryptamin- ergic neurones. This neuronal selectivity was antagonized by pretreatment of the rats with norzimeldine, a 5-HT uptake inhibitor, which indicates that these compounds are accumulated in the 5-HT nerve terminals by the 5-HT pump. 3 Selectivity was obtained for compounds with dimethyl, monomethyl or unsubstituted p-amino groups. An isopropyl group appears to substitute for the dimethylamino group but with considerably lower potency. Compounds with 2-substitution showed selectivity for aminergic neurones and this effect decreased with increased size of the substituent. The 2,6-dichloro derivative FLA 365 had, however, no neuronal selective action but was a potent MAO inhibitor. Substitutions in the 3- and 5- positions decreased both potency and selectivity. 4 Prolongation ofthe side chain with one methylene group abolished the preference for the MAO in 5-hydroxytryptaminergic neurones although the MAO inhibitory potency remained.
    [Show full text]
  • Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives Strucrure-Acfivity RELA TIONSHIPS Ma
    Biochemieal PhannaeoloR)'. Vol. 54. pp. 1361-1369, 1997. ISSN 0006-2952/97/$17.00 + 0.00 © 1997 Elsevier Scienee Ine. Al! rights reserved. PIl SOOO6-2952(97)00405·X ELSEVIER Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives STRUcruRE-ACfIVITY RELA TIONSHIPS Ma. Cecilia Scorza,* Cecilia Carrau,* Rodolfo Silveira,* GemId Zapata,Torres,t Bruce K. Casselst and Miguel Reyes,Parada*t *DIVISIÓNBIOLOGíACELULAR,INSTITUTODEINVESTIGACIONESBIOLÓGICASCLEMENTeEsTABlE, CP 11600, MONTEVIOEO,URUGUAY;ANDtDEPARTAMENTODEQUíMICA, FACULTADDECIENCIAS,UNIVERSIDADDECHILE, SANTIAGO,CHILE ABSTRACT. The monoamine oxidase (MAO) inhibitory propenies of a series of amphetamine derivatives with difTerent substituents at or around rhe para position of the aromaric ring were evaluateJ. i¡, in viero stuJies in which a crude rar brain mirochllndrial suspension was used as rhe source of MAO, several compounds showed a srrong (ICS0 in rhe submicromolar range), selecrive, reversible, time-independenr, and concenrrarion-related inhibition of MAO-A. After i.p. injection, the compounds induced an inerease of serotonin and a decrease of j-hydroxyindoleacetic acid in the raphe nuclei and hippocampus, confinning rhe in virro results. The analysis of structure-activity relationships indicates rhat: molecules with amphetamine-Iike structure and different substitutions nn the aromaric ring are potentially MAO-A inhibitors; substituents at different positions of the aromatic ring moditY the porency but have litde inf1uence "n the selectiviry; substituents at rhe para position sllch as ,lmino, alkoxyl. halogens. or alkylthio produce a significant increase in rhe acrivity; the para-substituent musr be an e1ectron Jonor; hulky ~roups next to rhe para subsriruent Icad ro a Jecrease in the actÍ\'ityi ,ubstiruents loearcd ar posirions more Jistant ,m rhe aromaric ring havc less intluence anJ, even when the subsriruent is '1 halogen (CI, Br), an increase in rhe acrivity "f rhe cllmpound is llbtained.
    [Show full text]
  • Brain CYP2D6 and Its Role in Neuroprotection Against Parkinson's
    Brain CYP2D6 and its role in neuroprotection against Parkinson’s disease by Amandeep Mann A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Pharmacology and Toxicology University of Toronto © Copyright by Amandeep Mann 2011 Brain CYP2D6 and its role in neuroprotection against Parkinson’s disease Amandeep Mann Doctor of Philosophy, 2011 Graduate Department of Pharmacology and Toxicology University of Toronto Abstract The enzyme CYP2D6 can metabolize many centrally acting drugs and endogenous neural compounds (e.g. catecholamines); it can also inactivate neurotoxins such as 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1,2,3,4-tetrahydroisoquinoline (TIQ) and β- carbolines that have been associated with Parkinson’s disease (PD). CYP2D6 is ideally situated in the brain to inactivate these neurotoxins. The CYP2D6 gene is also highly polymorphic, which leads to large variation in substrate metabolism. Furthermore, CYP2D6 genetically poor metabolizers are known to be at higher risk for developing PD, a risk that increases with exposure to pesticides. Conversely, smokers have a reduced risk for PD and smokers are suggested to have higher brain CYP2D6 levels. Our studies furthered the characterization and involvement of CYP2D6 in neuroprotection against PD. METHODS: We investigated the effects of CYP2D6 inhibition on MPP+-induced cell death in SH-SHY5Y human neuroblastoma cells. We compared levels of brain CYP2D6, measured by western blotting, between human smokers and non-smokers, between African Green monkeys treated with saline or nicotine, and between PD cases and controls. In addition, we assessed changes in human brain CYP2D6 expression with age.
    [Show full text]
  • Pharmacological Blockade of A2-Adrenoceptors Induces Reinstatement of Cocaine-Seeking Behavior in Squirrel Monkeys
    Neuropsychopharmacology (2004) 29, 686–693 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org Pharmacological Blockade of a2-Adrenoceptors Induces Reinstatement of Cocaine-Seeking Behavior in Squirrel Monkeys Buyean Lee*,1, Stefan Tiefenbacher1, Donna M Platt1 and Roger D Spealman1 1 Harvard Medical School, New England Primate Research Center, Southborough, MA, USA Converging evidence suggests a role for noradrenergic mechanisms in stress-induced reinstatement of cocaine seeking in animals. Yohimbine, an a -adrenoceptor antagonist, is known to be anxiogenic and induce stress-related responses in humans and animals. Here, 2 we tested the ability of yohimbine to reinstate cocaine-seeking behavior and induce behavioral and physiological signs characteristic of stress in squirrel monkeys. Monkeys were trained to self-administer cocaine under a second-order schedule of i.v. drug injection. Drug seeking subsequently was extinguished by substituting saline for cocaine injections and omitting the cocaine-paired stimulus. The ability of yohimbine and the structurally distinct a2-adrenoceptor antagonist RS-79948 to reinstate cocaine-seeking behavior was assessed by administering priming injections immediately before test sessions in which the cocaine-paired stimulus was either present or absent. Priming injections of yohimbine (0.1–0.56 mg/kg, i.m.) or RS-79948 (0.01–0.1 mg/kg, i.m.) induced dose-related reinstatement of cocaine- seeking behavior. The magnitude of yohimbine-induced reinstatement was similar regardless of the presence or absence of the cocaine- paired stimulus. Yohimbine also significantly increased salivary cortisol levels, a physiological marker of stress, as well as scratching and self- grooming, behavioral markers of stress in nonhuman primates.
    [Show full text]
  • In Vivo Characterization of a Novel Norepinephrine Transporter PET Tracer [18F]NS12137 in Adult and Immature Sprague-Dawley Rats Francisco R
    Theranostics 2019, Vol. 9, Issue 1 11 Ivyspring International Publisher Theranostics 2019; 9(1): 11-19. doi: 10.7150/thno.29740 Research Paper In vivo characterization of a novel norepinephrine transporter PET tracer [18F]NS12137 in adult and immature Sprague-Dawley rats Francisco R. López-Picón1,2*, Anna K. Kirjavainen3,4*, Sarita Forsback3,4, Jatta S. Takkinen1,2, Dan Peters5,6, Merja Haaparanta-Solin1,2, and Olof Solin3,4,7 1. Preclinical Imaging, Turku PET Centre, University of Turku, Turku, Finland 2. Medicity Research Laboratory, University of Turku, Turku, Finland 3. Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland 4. Department of Chemistry, University of Turku, Turku, Finland 5. DanPET AB, Malmö, Sweden 6. Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 7. Accelerator Laboratory, Åbo Akademi University, Turku, Finland *The authors contributed equally to this work Corresponding author: Francisco R. López-Picón, PhD, PET Preclinical Imaging, Medicity Research Laboratory, Turku PET Centre, Tykistökatu 6A, 4th floor, FI-20520 Turku, Finland. E-mail: [email protected]. Tel. +358-2-333-7019 © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2018.09.06; Accepted: 2018.11.16; Published: 2019.01.01 Abstract Norepinephrine modulates cognitive processes such as working and episodic memory. Pathological changes in norepinephrine and norepinephrine transporter (NET) function and degeneration of the locus coeruleus produce irreversible impairments within the whole norepinephrine system, disrupting cognitive processes.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Low Dose Pipamperone in Treating Mood and Anxiety Disorders
    (19) & (11) EP 2 236 138 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 06.10.2010 Bulletin 2010/40 A61K 31/4545 (2006.01) A61K 45/06 (2006.01) A61P 25/22 (2006.01) A61P 25/24 (2006.01) (2006.01) (21) Application number: 09156752.9 A61K 31/343 (22) Date of filing: 30.03.2009 (84) Designated Contracting States: • van der Geest, Ronald AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 4835 AA, Breda (BE) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR (74) Representative: De Clercq, Ann G. Y. et al Designated Extension States: De Clercq & Partners cvba AL BA RS Edgard Gevaertdreef 10 a 9830 Sint-Martens-Latem (BE) (71) Applicant: PharmaNeuroBoost N.V. 3570 Alken (BE) Remarks: Claim .17-19,21-24ed to be abandoned due to non- (72) Inventors: payment of the claims fee (Rule 45(3) EPC). • Buntinx, Erik 3570, Alken (BE) (54) Low dose pipamperone in treating mood and anxiety disorders (57) The present invention relates to the use of combinations comprising pipamperone and an SSRI, SNDRI or SNRI and compositions comprising the same for the treatment of mood or anxiety disorders. EP 2 236 138 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 236 138 A1 Description Field of the invention 5 [0001] The invention relates to the field of neuropsychiatry. More specifically, the invention relates to the use of pipamperone in augmenting and in a faster onset of serotonin re- uptake inhibitors, such as SSRIs, SNDRIs and SNRIs, in treating mood and anxiety disorders.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]